Angelo Pirozzi
Onco
Daily
Twitter
Facebook
Youtube
RSS Feed
Linkedin
Facebook
RSS
Twitter
Youtube
Linkedin
June, 2024
June 2024
M
T
W
T
F
S
S
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
« May
Angelo Pirozzi
Jun 10, 2024, 11:22 |
Blog
Angelo Pirozzi: Outstanding works from my colleagues and rising stars Rita Balsano and Giulia Tesini
Angelo Pirozzi, Research Fellow at Mayo Clinic, shared a post on X/Twitter: ''Outstanding works from my…
Jun 9, 2024, 09:31 |
Blog
Angelo Pirozzi: Update on FIGHT-202
Angelo Pirozzi, Research Fellow at Mayo Clinic, shared on X: "Update on FIGHT-202 145 patients with…
Jun 8, 2024, 09:58 |
Insight
Angelo Pirozzi: Circulating immune-related proteins might predict the efficacy of Immune Checkpoint Inhibitors
Angelo Pirozzi, Research Fellow at Mayo Clinic, shared on X: .…
May 31, 2024, 06:01 |
Blog
Andres Cardona: Mutational landscape of cancer-driver genes across human cancers
Angelo Pirozzi, Medical Oncology Fellow at Humanitas University and Research Fellow at Mayo Clinic (Phoenix),…
May 28, 2024, 08:56 |
Blog
Angelo Pirozzi: CAR-T cells targeting claudin18.2 in pretreated advanced PDAC by Changsong Qi et al.
Angelo Pirozzi, Medical Oncology Fellow at Humanitas University and Research Fellow at Mayo Clinic (Phoenix),…
May 25, 2024, 11:14 |
Blog
Angelo Pirozzi: Comprehensive review from Lorenzo Gervaso about Rationale of neoadjuvant immunotherapy in GI malignancies
Angelo Pirozzi, Medical Oncology Fellow at Humanitas University and Research Fellow at Mayo Clinic (Phoenix),…
May 11, 2024, 14:15 |
Career
Angelo Pirozzi: I’ve joined Mayo Clinic as a new research fellow in hepatobiliary and pancreatic cancers
Angelo Pirozzi, Medical Oncology Fellow at Humanitas University and Research Fellow at Mayo Clinic (Phoenix),…
All:
7
Posts:
1 - 10
Eliot Levitt: The Yvonne Awards demonstrate something that it doesn't hurt to be reminded of
New data from the NEST clinical trial was presented at ESMOGI24 - Agenus
Zainab Shinkafi-Bagudu's latest commentary on Cervical Cancer Elimination Forum
New Paper Alert! Amivantamab-Lazertinib Improves Outcomes in High-Risk EGFR-Mutant NSCLC Subgroups: MARIPOSA Study Results
Learn more about overcoming barriers to immunotherapy for microsatellite stable colorectal cancer
Facebook
RSS Feed
Twitter
Linkedin
Youtube